Arpita Desai, MD

HS Assoc Clinical Professor

Dr. Arpita Desai is a medical oncologist who specializes in the care of patients with genitourinary cancers, with a particular focus on kidney and prostate cancers. She serves as the Medical Director of the Genitourinary (GU) Medical Oncology Program at UCSF, where she leads efforts to deliver multidisciplinary, patient-centered care and advance innovative treatments.

Dr. Desai leads the UCSF Kidney Cancer Program, which brings together clinical care, translational research, and innovation to improve outcomes for patients with renal cell carcinoma (RCC). She also serves as Medical Director of the UCSF Von Hippel–Lindau (VHL) Multidisciplinary Clinic, which integrates oncology, genetics, nephrology, ophthalmology, neurosurgery, endocrinology, and other specialties to provide comprehensive, coordinated care for patients with VHL syndrome.

Her research is dedicated to developing novel imaging and therapeutic strategies for RCC. She is particularly interested in integrating functional and molecular imaging to personalize treatment and improve patient outcomes. Her translational research program spans theranostics, hyperpolarized MRI, and biomarker-driven approaches to optimize therapy selection in GU malignancies.

Dr. Desai completed her residency in internal medicine at the State University of New York, where she also served as chief resident. She then completed a fellowship in medical oncology at the University of Chicago. She is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines Panel.

Through her clinical leadership, research, and national collaborations, Dr. Desai is committed to advancing precision medicine in kidney cancer and improving the lives of patients through both cutting-edge clinical care and translational research.

Education
Fellowship, 2018 - Medical Oncology, University of Chicago
Residency, 2015 - Internal Medicine, State University of New York at Buffalo
Honors and Awards
  • Cancer Research Institute Investigator’s Technology Impact Award, CRI, 2025
  • UCSF Outstanding Mentorship Award, UCSF, 2024
  • UCSF Pilot Award in Precision Imaging of Cancer and Therapy, UCSF, 2024
  • Prostate Cancer Program Pilot Research Award, Prostate Cancer Program UCSF, 2022
  • HDFCC UCSF Junior Clinical Investigator Award, UCSF, 2020
  • Conquer Cancer Foundation of ASCO/Frances A. Shepherd, MD, Endowed Merit Award, ASCO, 2018
  • Young Investigator Award, IASLC, 2018
  • Thomas F. Frawley Research Fellowship Award, SUNY at Buffalo, 2015
  • Dexter S. Levy Memorial Award, SUNY at Buffalo, 2014
Publications
  1. Courau T, Desai A, Wagner A, Combes AJ, Krummel MF. The coming era of nudge drugs for cancer. Cancer cell 2025. PMID: 40939589


  2. Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S. YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study. Journal of the National Comprehensive Cancer Network : JNCCN 2025. PMID: 40154405


  3. Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, Belkora J. Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer medicine 2024. PMID: 39569542


  4. Sidhom F, Patel S, Desai A, Basu A. High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma-Are we there yet? Clinical genitourinary cancer 2024. PMID: 39536416


  5. Shakhnazaryan N, Gima-Lange L, Desai A, Fitzgerald K, Kwon DH. Accuracy, readability, and quality of websites about metastatic renal cell carcinoma treatment. Urologic oncology 2024. PMID: 38955572


  6. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. Journal of the National Comprehensive Cancer Network : JNCCN 2024. PMID: 38394781


  7. Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Science bulletin 2023. PMID: 38239394


  8. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. The Lancet. Oncology 2023. PMID: 37922930


  9. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clinical genitourinary cancer 2023. PMID: 37316414


  10. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Frontiers in oncology 2023. PMID: 37091148


  11. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urologic oncology 2022. PMID: 36435709


  12. Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. 2022. PMID: 35274720


  13. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. 2022. PMID: 35321431


  14. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 2022. PMID: 34991070


  15. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. 2021. PMID: 34932386


  16. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. Journal for immunotherapy of cancer 2021. PMID: 33980590


  17. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer 2021. PMID: 33690902


  18. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer medicine 2020. PMID: 33247633


  19. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in oncology 2020. PMID: 33194712


  20. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32886895


  21. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2019. PMID: 30975761